Myriad Genetics (NASDAQ: MYGN) CEO adds 3,542 shares via employee stock purchase plan

Rhea-AI Filing Summary

MYRIAD GENETICS INC President and CEO Samraat S. Raha acquired 3,542 shares of common stock on June 11, 2026. The shares were obtained at $3.936 per share under the company’s Amended and Restated 2012 Employee Stock Purchase Plan, as a compensation-related award.

After this acquisition, Raha directly holds 1,068,083 shares of Myriad Genetics common stock. This filing reflects a routine, plan-based share purchase rather than an open-market buy or sell decision.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Raha Samraat S.

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,542	$3.936	$14K

Holdings After Transaction: Common Stock — 1,068,083 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 3,542 shares Acquisition price: $3.936 per share Total shares held after: 1,068,083 shares

3 metrics

Shares acquired 3,542 shares Common stock acquired on June 11, 2026 under ESPP

Acquisition price $3.936 per share Price for ESPP acquisition of 3,542 common shares

Total shares held after 1,068,083 shares Direct holdings of CEO Samraat S. Raha after transaction

Key Terms

Amended and Restated 2012 Employee Stock Purchase Plan, Rule 16b-3(d), Rule 16b-3(c)

3 terms

Amended and Restated 2012 Employee Stock Purchase Plan financial

"These shares were acquired under the Issuer's Amended and Restated 2012 Employee Stock Purchase Plan"

Rule 16b-3(d) regulatory

"transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)"

Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.

Rule 16b-3(c) regulatory

"transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)"

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raha Samraat S.

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		3,542(1)	A	$3.936	1,068,083	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were acquired under the Issuer's Amended and Restated 2012 Employee Stock Purchase Plan, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	By: Justin Hunter For: Samraat S. Raha	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did MYRIAD GENETICS INC (MYGN) CEO Samraat Raha report in this Form 4?

Samraat S. Raha reported acquiring 3,542 shares of Myriad Genetics common stock. The shares were obtained through the company’s Amended and Restated 2012 Employee Stock Purchase Plan at $3.936 per share, increasing his direct holdings to 1,068,083 shares.

Was the MYGN CEO’s June 11, 2026 transaction an open-market stock purchase?

No, the CEO’s transaction was not an open-market purchase. The 3,542 shares were acquired under Myriad Genetics’ Amended and Restated 2012 Employee Stock Purchase Plan, in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating a routine, plan-based acquisition.

How many MYRIAD GENETICS INC (MYGN) shares does CEO Samraat Raha hold after this Form 4?

After the reported transaction, Samraat S. Raha directly holds 1,068,083 shares of Myriad Genetics common stock. This total reflects the addition of 3,542 shares acquired through the company’s employee stock purchase plan at $3.936 per share on June 11, 2026.

What does the $3.936 price in the MYGN Form 4 represent?

The $3.936 figure represents the per-share price for the 3,542 Myriad Genetics shares acquired by CEO Samraat S. Raha. These shares were purchased under the Amended and Restated 2012 Employee Stock Purchase Plan, as disclosed in the Form 4 and related footnote describing the exempt transactions.

What is the significance of Rule 16b-3(d) and 16b-3(c) in the MYGN CEO’s Form 4?

The footnote explains the transactions were exempt under Rule 16b-3(d) and Rule 16b-3(c). These provisions allow certain officer and director transactions, like plan-based acquisitions, to be exempt from short-swing profit rules, underscoring this event as routine compensation-related activity rather than discretionary trading.

What plan was used for the MYGN CEO’s 3,542-share acquisition?

The 3,542 shares were acquired under Myriad Genetics’ Amended and Restated 2012 Employee Stock Purchase Plan. This plan allows eligible employees, including the CEO, to obtain company stock through structured purchases, and the Form 4 notes the transactions qualify for exemptions under Rule 16b-3 provisions.